TABLE 2

Utility of exacerbation or hospitalisation due to exacerbation

StudyInstrumentReport formatResults
Alcazar et al. [19]EQ-5D VASMean±sdHospitalised patients: 0.551±0.197
Antoniu et al. [20]EQ-5D VASMean±sdHospitalised patients: 0.279±0.252
Bourbeau et al. [47]EQ-5D VASMean±sdChange from baseline: −0.126±0.190
Cross et al. [21]EQ-5D VASMean±sdExacerbation of COPD: manual chest physiotherapy arm 0.450±0.210; no manual chest physiotherapy arm 0.466±0.214
EQ-5D utilityMean±sdExacerbation of COPD: manual chest physiotherapy arm 0.450±0.320; no manual chest physiotherapy arm 0.430±0.360
Goossens et al. [22]EQ-5D VASMean±sdExacerbation (at enrolment): 0.367±0.252
EQ-5D utilityMean±sdExacerbation (at enrolment): 0.683±0.209
Menn et al. [39]EQ-5D utilityMean±sdEQ-5D Admission Stage III: 0.620±0.260
EQ-5D Admission Stage IV: 0.600±0.260
SF-6D utilityMean±sdSF-12-SF-6D Admission Stage III: 0.610±0.130
SF-12-SF-6D Admission Stage IV: 0.540±0.080
Miravitlles et al. [23]EQ-5D utilityMean±sdEQ-5D index baseline (exacerbation): 0.540±0.230
EQ-5D VASMean±sdEQ VAS baseline (exacerbation): 0.344±0.274
O'Reilly et al. [24]EQ-5D utilityMean±sdHospital admission: −0.077±0.397
EQ-5D VASHospital admission: 0.259±0.170
Punekar et al. [43]EQ-5D utilityMean (95% CI)1–2 exacerbations in primary care physician setting: 0.740 (0.720–0.770)
>3 exacerbations in primary care physician setting: 0.610 (0.590–0.640)
1–2 exacerbations in respiratory specialist setting: 0.730 (0.710–0.760)
>3 exacerbations in respiratory specialist setting: 0.570 (0.540–0.600)
Rutten van Molken et al. [27]VASRegression coefficient±sem1 nonserious exacerbation: −0.037±0.005
2 nonserious exacerbations: −0.068±0.005
1 serious exacerbation: −0.090±0.007
1 nonserious and 1 serious exacerbation: −0.130±0.007
TTO1 nonserious exacerbation: −0.010±0.007
2 nonserious exacerbations: −0.021±0.007
1 serious exacerbation: −0.042±0.009
1 nonserious and 1 serious exacerbation: −0.088±0.009
Seymour et al. [25]EQ-5D VASMean±sdCOPD baseline in usual care group: 0.540±0.170
COPD baseline in post-exacerbation pulmonary rehabilitation group: 0.580±0.180
Solem et al. [40]EQ-5D utilityMean±sdPatients recently experiencing a severe exacerbation: 0.627±0.210
Patients recently experiencing a moderate exacerbation. 0.698±0.197
Patients who had experienced ≥3 exacerbations in the previous year: 0.638±0.212
Patients who had experienced 2 exacerbations in the previous year: 0.684±0.204
Patients who had experienced 1 exacerbation in the previous year: 0.727±0.175
Current health (last exacerbation): 0.552±0.283
Thought back, patients experiencing a severe exacerbation (last exacerbation): 0.471±0.313
Thought back, patients experiencing a moderate exacerbation (last exacerbation): 0.595±0.257
Very severe COPD (last exacerbation): 0.494±0.312
Severe COPD (last exacerbation): 0.590±0.256
Patients who had experienced ≥3 exacerbations in the previous year (last exacerbation): 0.520±0.282
Patients who had experienced 2 exacerbations in the previous year (last exacerbation): 0.552±0.306
Patients who had experienced one exacerbation in the previous year (last exacerbation): 0.610±0.254
Torrance et al. [48]HUIMean±sdFor the first acute exacerbation of chronic bronchitis: ciprofloxacin group: 0.720±0.200); usual care group 0.680±0.190
For the remaining acute exacerbation of chronic bronchitis: ciprofloxacin group: 0.740±0.180; usual care group 0.690±0.220
Wildman et al. [26]EQ-5D VASMean±sd0.549±0.195
Median (IQR)0.500 (0.400–0.700)

EQ-5D: EuroQol-5D; VAS: visual analogue scale; TTO: time trade-off; HUI: Health Utility Index; IQR: interquartile range; COPD: chronic obstructive pulmonary disease.